Expert Perspectives on Fixed Duration Therapy with Venetoclax + Obinutuzumab

Opinion
Video

A panel of experts discuss the role of fixed duration therapy with venetoclax and obinutuzumab, outlining their general approach for patient selection.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
We have the current CAR [T-cell therapies], which target CD19; however, we need others.
Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
Related Content
Cellular therapies are a treatment modality that hold promise in various cancer types.

Cross-Collaboration is Key for Cellular Therapies Options Across Cancer Types

Tim Cortese
August 16th 2025
Article
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 16th 2025
Podcast
Durable Response to CAR T is Associated With Elevated Activation and Clonotypic Expansion of the Cytotoxic Native T Cell Repertoire

Durable Response to CAR T is Associated With Elevated Activation and Clonotypic Expansion of the Cytotoxic Native T Cell Repertoire

American Society for Transplantation and Cellular Therapy
August 16th 2025
Article
An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
August 16th 2025
Podcast
Data from the phase 3 BRUIN CLL-314 trial show a progression-free survival trend favoring pirtobrutinib compared with ibrutinib in patients with CLL/SLL.

Pirtobrutinib Yields Noninferior ORR Vs Ibrutinib in CLL/SLL

Russ Conroy
August 16th 2025
Article
AMPLIFY trial results form the basis of the submission, with venetoclax/acalabrutinib showing a PFS advantage vs chemoimmunotherapy in patients with CLL.

sNDA Submitted to FDA for Venetoclax Plus Acalabrutinib in Untreated CLL

Roman Fabbricatore
August 16th 2025
Article